Tag Archives | pharmacogenomics

JPMorgan Healthcare Conference Notes #4: Next Gen Sequencing (NGS)

Seminar: Harnessing the Power of Next Gen Sequencing: The View from Industry 1/12/15 A panel of leading entrepreneurial R&D executives presented their outlook and issues on the future of Next Gen Sequencing (NGS), focusing on drug development and future clinical diagnostic applications. The panel was Randy Scott Ph.D. Founder and CEO of Invitae, George Yancopoulos […]

Continue Reading 0

JPMorgan Healthcare Conference Notes #1: Sequencing Picks Romp-FMI

Sequencing Remains Hot-Roche (RHHBY) Deal With Foundation Medicine (FMI) Worth $1.1B Targeted Oncology Therapy-Molecular information from pathways and biomarkers e.g. PDL-1 RNA based immunotherapy test Continuous  monitoring of tumor specific information and molecular alterations All of our sequencing picks were up  1/12 on Roche equity deal to support oncology with personalized medicine development. Two other […]

Continue Reading 0

2015 Biotech Stock Preview: Rhythms of the “PermaBull”

2015: Another Good Year Unless “Something Happens” Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as there were  two major corrections in April 2014 after the Q1 “bio-bubble” […]

Continue Reading

Happy New Year 2015!

Wishing you all a Happy and Prosperous New Year! Biotech stocks were up 47% in 2014. In 2014 the first quarter was the most volatile. Sign up now to receive all of our market and portfolio updates. In December we posted updates on our Rayno Life Science Portfolios: Rayno Diagnostics and Tools Part 2: Rayno […]

Continue Reading

Rayno Life Science Stocks: YTD Review Part 1-FBT Up 49%

Part 1 Biopharmaceutical Stocks-New Highs Were Hit on December 10 Five Straight Years of Gains in Biotech-the IBB is up 292% since Dec 18, 2009 Biotech stocks are following the long term seasonal bullish trend surging in Q4 and up about 49 % YTD. The easiest way to invest in the biotech market is with […]

Continue Reading